Safety and Effectiveness Study Comparing Dabigatran, Rivaroxaban & Apixaban in Non-valvular Atrial Fibrillation Patients Enrolled in the US Department of Defense Military Health System

Trial Profile

Safety and Effectiveness Study Comparing Dabigatran, Rivaroxaban & Apixaban in Non-valvular Atrial Fibrillation Patients Enrolled in the US Department of Defense Military Health System

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jan 2018

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Apixaban; Rivaroxaban
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 26 Jan 2018 Results assessing stroke and major bleeding risks presented at the International Stroke Conference 2018
    • 25 Jan 2018 According to a Boehringer Ingelheim Pharmaceuticals media release, results were presented at the International Stroke Conference 2018.
    • 25 Jan 2018 Results presented in a Boehringer Ingelheim Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top